450.46 % to Target, H.C. Wainwright Reconfirms ‘Buy’ Rating on Ampliphi Biosciences (APHB) Shares Today

May 16, 2018 - By Henry Gaston

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Logo

Ampliphi Biosciences (APHB) Rating Reaffirmed

The financial firm has just set a target price per share of $6.0000 on Ampliphi Biosciences (APHB) shares. This is 450.46 % from the previous close. In an analyst note revealed to investors on Wednesday, 16 May, H.C. Wainwright maintained their Buy rating on shares of APHB.

The stock decreased 7.92% or $0.09 during the last trading session, reaching $1.09. About 273,453 shares traded. AmpliPhi Biosciences Corporation (APHB) has declined 77.34% since May 17, 2017 and is downtrending. It has underperformed by 88.89% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $17.95 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: